PATH vs SLS · P/E 19, rev $1.61B vs $1.62B cap
Uipath Inc (PATH) versus Sellas Life Sciences Group Inc (SLS) — a side-by-side from cached financials, not a winner call.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Sellas Life Sciences Group Inc (SLS) is a biotechnology company listed on US.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Latest reported SLS revenue for 2026-06-30 was $0. Net income was -$9.6M. SLS currently screens at market cap $1.62B.
PATH currently screens at market cap $6.07B and trailing P/E 19.4. SLS currently screens at market cap $1.62B.
Not investment advice. Open the PATH and SLS stock pages for the full models.
Not investment advice.